SEQURNA moving forward with industrial partner Genovis

Yesterday the news was shared that the Swedish biotech company Genovis has invested and partnered with our DRIVE incubator company SEQURNA. This is extremely exciting, and we are happy about their progress. We have worked with Björn Reinius (CEO) and his team since 2021 when they entered our START innovation support program to explore the commercial potential in an RNA research reagent. Since then, they have moved fast. In 2022 they formed SEQURNA as a spin-off from Björn Reinius’ lab at KI and entered the DRIVE incubator program in parallel with KI Holding making a first investment into the company. Already by 2023 they made their first pilot sales and now they are more than ready to scale for global distribution. As world-leading scientists in RNA research the team behind SEQURNA are also key-opinion-leaders in their own field. Their first product is a synthetic thermostable RNAse inhibitor with equal or superior properties to state-of-the-art protein-based RNAse inhibitors. On top of that, the product has an excellent sustainability profile since it can be shipped in an envelope without the need of several kilograms of dry ice.

“With Swedish biotech firm Genovis SEQURNA has found the ideal partner. Their experience in building a product company as well access to Genovis international distribution network is exactly what SEQURNA needs to scale fast. This will be exciting to follow!”, says Johan Weigelt CEO of KI Holding and KI Innovations.

“I’m really happy to have formed this partnership with Genovis and pleased to be contributing to the Swedish biotech industry by doing so”, says Björn Reinius, CEO of SEQURNA.

 With a market-ready product I’m confident this is the best way to continue to build SEQURNA. I’m also very grateful for all the support we’ve received from KI Innovations and KI Holding over the past years. Without them we would not be where we are today!”, continues Björn.

Link to the press release: https://lnkd.in/d__Hste5